Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Authors
Lassen, UChinot, O
McBain, Catherine A
Mau-Sørensen, M
Larsen, V
Barrie, M
Roth, P
Krieter, O
Wang, K
Habben, K
Tessier, J
Lahr, A
Weller, M
Affiliation
Department of Oncology, Rigshospitalet, Copenhagen, DenmarkIssue Date
2015-02-09
Metadata
Show full item recordAbstract
We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclonal antibody, to establish the recommended dose for use with bevacizumab and to investigate the pharmacokinetics, pharmacodynamics, safety/tolerability, and preliminary clinical efficacy of the combination.Citation
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. 2015: Neuro-oncologyJournal
Neuro-oncologyDOI
10.1093/neuonc/nov019PubMed ID
25665807Type
ArticleLanguage
enISSN
1523-5866ae974a485f413a2113503eed53cd6c53
10.1093/neuonc/nov019
Scopus Count
Collections
Related articles
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker Analyses.
- Authors: Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS
- Issue date: 2017 Jan 20
- An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism.
- Authors: Wang K, Stark FS, Schlothauer T, Lahr A, Cosson V, Zhi J, Habben K, Tessier J, Schick E, Staack RF, Krieter O
- Issue date: 2017 Apr
- [Treatment of recurrent glioblastoma with single-agent bevacizumab].
- Authors: Sinkó D, Nemeskéri C
- Issue date: 2016 Mar 27
- Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
- Authors: Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS
- Issue date: 2010 May
- Ipilimumab and Bevacizumab in Glioblastoma.
- Authors: Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P
- Issue date: 2016 Oct